BRAF and hairy cell leukemia: For example, the BRAFV600E mutation is a frequent and well-described driver mutation in melanoma and hairy cell leukemia with approximate response rates of 50–60% and 96–100%, respectively, to BRAF inhibition with tyrosine kinase inhibitors37–39.